Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

JAMA Oncology Author Interviews
16/09/2021 34 min
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Listen "Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Laura J. Esserman, MD, and W. Fraser Symmans, MD, authors of Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial

More episodes of the podcast JAMA Oncology Author Interviews

Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality 30/10/2025
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer 18/09/2025
Proportional Sedation for Persistent Agitated Delirium in Palliative Care 31/07/2025
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance 29/05/2025
Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury 24/04/2025
Accelerated Aging in Survivors of Childhood Cancer 20/03/2025
Academic-Community Partnership and Deaths in Promyelocytic Leukemia 27/02/2025
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy 30/01/2025
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 05/12/2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib 21/11/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA